On December 7, 2020 Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, reported efficacy data from a study of JBI-802, its novel dual inhibitor of LSD1-HDAC6, in multiple acute myeloid leukemia (AML) models, and the identification of novel, undisclosed biomarkers that will aid in patient stratification (Press release, Jubilant Therapeutics, DEC 7, 2020, View Source [SID1234572383]). The data, presented today in a poster session at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Virtual Annual Meeting, demonstrate superior efficacy in select AML models as compared to single agent inhibitors, with a unique mechanism of action.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are highly encouraged to verify that both LSD1 and HDAC6 mechanisms are operational with JBI-802 and the dual inhibition shows a stronger and more potent effect than the standalone inhibitors. We are also excited about the potential biomarkers we have identified specifically for the dual inhibitor which will be highly valuable in identifying sensitive patient populations," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. "We believe JBI-802 could one day serve as a powerful therapeutic agent for the treatment of specific cancers, including myelodysplastic syndrome (MDS), select acute myeloid leukemia (AML) and solid tumor subsets."
A link to the abstract, Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer, is available through the ASH (Free ASH Whitepaper) conference website.
Key highlights from the study of JBI-802 as compared to single agent LSD1 or HDAC6 selective inhibitors in AML models show:
Both LSD1 and HDAC6 mechanisms are operational with JBI-802 resulting in stronger anti-proliferation and efficacy in a subset of cell lines;
Selective biomarkers are modulated with the dual inhibition of JBI-802 not seen by the single agent inhibitors, leading to the potential for patient stratification and the evaluation of treatment response; and
JBI-802 has a superior efficacy, safety and tolerability profile.